STOCK TITAN
  1. Home
  2. Sec-filings
  3. LKFT
  4. [6-K] Lakefront Biotherapeutics NV Current Report (Foreign Issuer)

Eric Hedrick becomes Chief Medical Officer at Lakefront Biotherapeutics (LKFT) amid pipeline shift

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics appointed Eric Hedrick, MD, as Chief Medical Officer, expanding its leadership team during a strategic transformation that follows the acquisition of Ouro Medicines’ operational assets announced on June 4, 2026.

Hedrick, who joined Lakefront in July 2025, has 25 years of experience developing successful therapies at several biotechnology companies. He will report to CEO Henry Gosebruch, join the Management Committee, and lead development of gamgertamig and future clinical programs within Lakefront’s oncology and immunology-focused R&D pipeline.

Positive

  • None.

Negative

  • None.
Appointment date June 8, 2026 Eric Hedrick named Chief Medical Officer
Ouro assets acquisition announcement June 4, 2026 Acquisition of Ouro Medicines operational assets
Industry experience 25 years Hedrick’s track record developing therapies
Join date at Lakefront July 2025 Hedrick joined as clinical evaluation lead
Chief Medical Officer financial
"Lakefront Biotherapeutics NV ... announced that Eric Hedrick, MD has been appointed Chief Medical Officer."
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
strategic transformation financial
"This expanded leadership role supports the Company’s strategic transformation following its acquisition of Ouro Medicines operational assets."
A strategic transformation is a planned, company-wide change in how a business operates, competes, or makes money—such as shifting products, reorganizing teams, adopting new technology, or entering new markets. For investors it matters because these shifts aim to improve long-term growth or profitability but carry risks and costs up front; think of it like remodeling a house to increase its value—potentially higher returns, but with disruption and uncertainty during the work.
R&D pipeline financial
"The Ouro portfolio is now the cornerstone of Lakefront’s R&D pipeline and I’m thrilled to have a talented drug developer..."
A company's R&D pipeline is the lineup of products, drug candidates or technologies under development, organized from early ideas through testing to near-ready offerings. For investors it acts like a sports team's prospect list: the number, stage and likelihood of success of items in the pipeline indicate future revenue potential, scientific or regulatory risk, and how the company’s value might change as projects progress or fail.
forward-looking statements regulatory
"Forward-looking statements This press release may include forward-looking statements, all of which involve certain risks and uncertainties."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Form 20-F regulatory
"our most recent annual report on Form 20‐F filed with the SEC, as supplemented and/or modified by any other filings..."
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, except for the quotes of Mr. Henry Gosebruch, included in Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On June 8, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated June 8, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: June 9, 2026     /s/ Annelies Denecker    
  Annelies Denecker
  Company Secretary
  

EXHIBIT 99.1

Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer

Mechelen, Belgium; June 8, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership role supports the Company’s strategic transformation following its acquisition of Ouro Medicines operational assets announced on June 4, 2026.1 Eric will report to Henry Gosebruch, CEO and join the Company’s Management Committee.

“Eric has been an invaluable contributor over this past year, driving our clinical assessments and partnering with our external colleagues,” said Henry Gosebruch, Chief Executive Officer of Lakefront. “The Ouro portfolio is now the cornerstone of Lakefront’s R&D pipeline and I’m thrilled to have a talented drug developer of Eric’s caliber and experience to guide the development of gamgertamig and our future clinical programs.”

Dr. Hedrick has a twenty-five year track record successfully developing effective and commercially successful therapies in the pharmaceutical and biotechnology industry. Prior to joining Lakefront in July, 2025 to serve as clinical evaluation lead for new pipeline opportunities, Dr. Hedrick held roles as Chief Executive Physician at EQRx, Chief Advisor and Interim Chief Medical Officer for BeiGene, Chief Medical Officer at Epizyme and Interim Chief Medical Officer at Pharmacyclics. Dr. Hedrick started his career in biotechnology at Genentech. He received his M.D. from the University of Maryland and was previously an attending physician at the Memorial Sloan-Kettering Cancer Center.

About Lakefront® Biotherapeutics
Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Forward-looking statements
This press release may include forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as “will,” “long-term,” and “forward,” and any similar expressions. These statements include, but are not limited to, statements regarding the announced leadership appointment; Mr. Hedrick’s expected responsibilities and potential contributions to the company, and the company’s strategic transformation and pipeline. Any forward-looking statements in this press release are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve unknown and known risks, uncertainties, and other factors which might cause our actual results, performance, or achievements to be materially different from any historic or future results, performance, or achievements expressed or implied by such statements. These risks, uncertainties, and other factors include, without limitation, the risk that Lakefront will encounter challenges retaining or attracting talent, that our leadership transition may be disruptive to our business operations, and risks related to our ability to effectively transfer knowledge during this period of transition. A further list and description of these risks, uncertainties, and other factors can be found in our filings and reports with the Securities and Exchange Commission (SEC), including in our most recent annual report on Form 20‐F filed with the SEC, as supplemented and/or modified by any other filings and reports that we have made or will make with the SEC in the future. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if our results, performance, or achievements are consistent with such forward-looking statements, they may not be predictive of results, performance, or achievements in future periods. These forward-looking statements speak only as of the date of publication of this press release. We expressly disclaim any obligation to update any forward-looking statements in this press release, unless required by law or regulation.

1 See GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE - Lakefront Biotherapeutics for further details

Source: View Original Filing on SEC EDGAR

FAQ

What leadership change did Lakefront Biotherapeutics (LKFT) announce in this 6-K?

Lakefront Biotherapeutics appointed Eric Hedrick, MD, as Chief Medical Officer. He will report to CEO Henry Gosebruch, join the Management Committee, and oversee development of gamgertamig and future clinical programs in the company’s oncology and immunology-focused pipeline.

How does Eric Hedrick’s role relate to Lakefront Biotherapeutics’ (LKFT) Ouro Medicines acquisition?

Eric Hedrick’s expanded role supports Lakefront’s strategic transformation after acquiring Ouro Medicines’ operational assets. The company states that the Ouro portfolio is now the cornerstone of Lakefront’s R&D pipeline, and Hedrick will guide development of gamgertamig and related clinical programs.

What experience does Eric Hedrick bring to Lakefront Biotherapeutics (LKFT)?

Eric Hedrick brings a 25-year track record in developing effective, commercially successful therapies. He previously held senior roles at EQRx, BeiGene, Epizyme and Pharmacyclics, began his biotech career at Genentech, and was an attending physician at Memorial Sloan-Kettering Cancer Center.

When did Eric Hedrick join Lakefront Biotherapeutics (LKFT) before becoming CMO?

Eric Hedrick joined Lakefront Biotherapeutics in July 2025 as clinical evaluation lead for new pipeline opportunities. After contributing to clinical assessments and external collaborations, he has now been appointed Chief Medical Officer to oversee gamgertamig and future clinical development programs.

What therapeutic areas does Lakefront Biotherapeutics (LKFT) prioritize?

Lakefront Biotherapeutics prioritizes oncology and immunology & inflammation programs. The company focuses on assets with clear clinical proof-of-concept in emerging areas and uses a modality-agnostic selection approach to advance medicines for serious diseases with unmet medical need.

What forward-looking statement risks does Lakefront Biotherapeutics (LKFT) highlight?

Lakefront notes risks that include challenges retaining or attracting talent, potential disruption from leadership transitions, and effective knowledge transfer. It directs readers to its SEC filings, including the most recent Form 20-F, for additional details on risks, uncertainties, and other important factors.

Filing Exhibits & Attachments

1 document

Press Releases